Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Depreciation & Amortization (CF): 2022-2024

Historic Depreciation & Amortization (CF) for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to $308,000.

  • Orchestra BioMed Holdings' Depreciation & Amortization (CF) rose 6.58% to $81,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $329,000, marking a year-over-year increase of 11.15%. This contributed to the annual value of $308,000 for FY2024, which is 7.32% up from last year.
  • According to the latest figures from FY2024, Orchestra BioMed Holdings' Depreciation & Amortization (CF) is $308,000, which was up 7.32% from $287,000 recorded in FY2023.
  • In the past 5 years, Orchestra BioMed Holdings' Depreciation & Amortization (CF) registered a high of $308,000 during FY2024, and its lowest value of $222,000 during FY2022.
  • For the 3-year period, Orchestra BioMed Holdings' Depreciation & Amortization (CF) averaged around $272,333, with its median value being $287,000 (2023).
  • Data for Orchestra BioMed Holdings' Depreciation & Amortization (CF) shows a peak YoY rose of 29.28% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Orchestra BioMed Holdings' Depreciation & Amortization (CF) stood at $222,000 in 2022, then increased by 29.28% to $287,000 in 2023, then climbed by 7.32% to $308,000 in 2024.